FUSO CHEMICAL (4368) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The company maintained revenue and profit growth as well as high profitability, primarily driven by the expansion of its Electronic Materials and Functional Chemicals Business. Revenue was ¥579.3B (+10.5% year on year), Operating Income was ¥145.6B (+15.6%), Ordinary Income was ¥150.7B (+14.6%), and Net Income was ¥106.9B (+16.6%). The growth rate in Operating Income exceeded the revenue growth rate, confirming margin improvement resulting from the rising contribution of high-margin segments.

Factors Affecting Performance

【Revenue】Revenue was ¥579.3B, representing a 10.5% year-on-year increase. The Electronic Materials and Functional Chemicals Business grew significantly to ¥315.3B (+26.6% year on year), with its revenue contribution rising from 47.5% to 54.4%. In contrast, the Life Science Business recorded revenue of ¥264.0B, a 4.0% year-on-year decline, highlighting the divergent performance of the two businesses.

【Profit and Loss】Operating Income was ¥145.6B (+15.6% year on year), and the Operating Margin of 25.1% improved by approximately 1.1pt from the same period of the previous year. Segment profit for the Electronic Materials and Functional Chemicals Business was ¥124.5B (+21.2%), with a margin of 39.5%, slightly down from 41.2% in the previous year, but the business remains the primary driver of consolidated profit. Segment profit for the Life Science Business was ¥39.1B (▲2.9% year on year), with a margin of 14.8%. Ordinary Income of ¥150.7B and Net Income of ¥106.9B both grew at rates exceeding that of Operating Income, supported by non-operating income, including foreign exchange gains of ¥2.7B, and extraordinary income, including a gain on the sale of investment securities of ¥1.8B. In conclusion, the company achieved revenue and profit growth, with the primary driver being an improved business mix resulting from the rising contribution of the high-margin Electronic Materials and Functional Chemicals Business.

Segment Analysis

The reported segments comprise the Life Science Business and the Electronic Materials and Functional Chemicals Business. The Electronic Materials and Functional Chemicals Business maintained high profitability, with revenue of ¥315.3B (+26.6% year on year), segment profit of ¥124.5B (+21.2%), and a margin of 39.5%, accounting for the majority of consolidated Operating Income. The Life Science Business recorded revenue of ¥264.0B (▲4.0% year on year), segment profit of ¥39.1B (▲2.9%), and a margin of 14.8%. Although the business showed a modest recovery in profitability, its revenue decline continues. The profitability gap between the segments is substantial, and the improvement in the company-wide profit margin is primarily attributable to changes in the business mix.

Key Financial Metrics

【Profitability】The Operating Margin was 25.1%, improving from approximately 24.0% in the previous year; the Net Margin was 18.4%, improving from approximately 17.5%; and the Gross Margin remained high at 38.5%. 【Cash Flow Quality】Operating Cash Flow (OCF) was ¥151.8B, or 1.42 times Net Income, indicating good cash conversion, although the OCF/EBITDA ratio remained at 0.69 times, with an increase in trade receivables of ¥20.9B and an increase in inventories of ¥5.9B weighing on working capital. 【Investment Efficiency】ROE was 9.4%. Despite the high Net Margin, the total asset turnover ratio was low at 0.39 times, constraining capital efficiency. Capital expenditures were ¥29.4B versus depreciation and amortization of ¥73.5B, resulting in a CapEx/depreciation and amortization ratio of only 0.40 times. 【Financial Soundness】The Equity Ratio was 75.7%, cash and deposits were ¥367.3B, and long-term borrowings were ¥140.0B, indicating an extremely stable financial base.

Cash Flow Analysis

Operating Cash Flow was ¥151.8B, a slight 5.7% year-on-year decline, but its ratio to Net Income of ¥106.9B was 1.42 times, indicating good cash conversion of earnings. Investing Cash Flow represented an outflow of ¥65.3B, primarily comprising capital expenditures of ¥29.4B and the acquisition of intangible fixed assets. Financing Cash Flow represented an outflow of ¥48.0B, mainly attributable to dividend payments of ¥27.8B and debt repayments of ¥20.0B. As a result, the company secured positive Free Cash Flow of ¥86.5B, providing sufficient capacity to fund dividend payments and debt repayments. However, an increase in trade receivables of ¥20.9B, an increase in inventories of ¥5.9B, and a ¥5.0B decrease in trade payables reduced Operating Cash Flow, indicating that the expansion of working capital associated with growth is somewhat constraining cash conversion efficiency.

Earnings Quality

The increase in current-period profit was primarily attributable to the expansion of Operating Income from the core business, with improved recurring earnings power being the central factor. Extraordinary income totaled ¥1.9B, mainly comprising a ¥1.8B gain on the sale of investment securities, while extraordinary losses were limited to ¥0.3B, including losses on the disposal of fixed assets. The resulting net one-time factor of ¥1.6B was minor, representing approximately 1.1% of Profit Before Tax of ¥152.4B. Within non-operating income and expenses, foreign exchange gains of ¥2.7B and interest income of ¥3.1B exceeded non-operating expenses, including interest expenses of ¥1.0B, resulting in Ordinary Income exceeding Operating Income. Comprehensive Income was ¥118.5B, exceeding Net Income of ¥106.9B, primarily due to a ¥12.2B increase in foreign currency translation adjustments. While Operating Cash Flow exceeded Net Income, some accruals arose from increases in trade receivables and inventories. Overall earnings quality was favorable, although developments in working capital require attention.

Earnings Forecasts and Guidance

The full-year company forecasts are revenue of ¥755.0B (+8.6% year on year), Operating Income of ¥175.0B (+7.8%), and Ordinary Income of ¥176.0B (+6.3%). The Q3 cumulative progress rates were 76.7% for revenue, 83.2% for Operating Income, and 85.6% for Ordinary Income, all exceeding the standard 75% progress benchmark. Profit progress exceeding revenue progress reflects the rising contribution of the high-margin Electronic Materials and Functional Chemicals Business, making demand trends in that business during Q4 a key factor determining full-year results.

Shareholder Returns

The Q2 dividend was ¥41.00 per share, while the full-year forecast dividend is ¥82.00 per share. The Payout Ratio based on cumulative Q3 Net Income was approximately 13.6%, while the forecast Payout Ratio based on forecast full-year Net Income of ¥122.0B was approximately 23.9%, significantly below the general benchmark of 60%. No material share repurchases were conducted (¥0.0B on a cash flow basis), and the Payout Ratio shown is based solely on dividends. Given the financial base of cash and deposits of ¥367.3B and Free Cash Flow of ¥86.5B, the company has substantial cash capacity to support dividend payments.

Risk Factors

1. Business Portfolio Concentration Risk: The Electronic Materials and Functional Chemicals Business is the core business, accounting for 54.4% of revenue and a segment profit margin of 39.5%. Consequently, cyclical fluctuations in semiconductor and electronic component demand, as well as customer inventory adjustments, could materially affect consolidated performance.

2. Deterioration in Working Capital Efficiency: Due to a ¥20.9B increase in trade receivables and accumulated inventories of ¥135.8B, primarily comprising products of ¥135.8B, the OCF/EBITDA ratio remained at 0.69 times. If the demand outlook changes, the risks of inventory valuation losses and production adjustments will increase.

3. Relative Restraint in Capital Expenditures: Capital expenditures of ¥29.4B amounted to only 0.40 times depreciation and amortization of ¥73.5B. Given the capital-intensive production base represented by property, plant and equipment of ¥647.2B, a continued shortfall in renewal and capacity expansion investment could affect medium- to long-term supply capacity and competitiveness.

Industry Benchmark (For Reference; Based on Company Research)

Profitability and Returns

Both the company’s Operating Margin and Net Margin significantly exceed the manufacturing industry median, indicating high profitability within the industry.

Growth and Capital Efficiency

The revenue growth rate also significantly exceeds the industry median, placing the company among the industry leaders in terms of growth.

※Source: Company research

Key Points in the Earnings Results

1. The Operating Margin of 25.1% and Net Margin of 18.4% are significantly above the industry average, primarily due to the rising contribution of the Electronic Materials and Functional Chemicals Business. Demand trends in this business will determine the future profitability trend.

2. ROE of 9.4% is supported by a high profit margin, while the total asset turnover ratio remains low at 0.39 times. This represents a monitoring point from the perspective of capital efficiency, given the company’s substantial cash holdings and equity.

3. The OCF/EBITDA ratio of 0.69 times and CapEx/depreciation and amortization ratio of 0.40 times indicate the expansion of working capital during a growth phase and relatively restrained capital expenditures. These metrics warrant attention from both the perspectives of cash conversion efficiency and the maintenance of future production capacity.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥3,308–¥3,505 at ±1% for the Cost of Equity, and ¥3,400–¥3,412 at ±0.1 for ω.

Notes:

• Since cumulative Net Income progress against the full-year forecast is 88%, exceeding the standard 75%, forecast EPS has been adjusted upward within a maximum range of +10% (because companies ahead of schedule in terms of progress tend to outperform their forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net assets as of the quarter-end have been used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit five-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market stock price or a recommendation for any specific investment action, and does not predict or guarantee the future stock price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 was a strong earnings period, led by robust expansion in the Electronic Materials and Functional Chemicals business while the Life Science business softened modestly. Cumulative revenue rose 10.5% year on year to ¥57.93bn. Operating income increased faster, by 15.6% to ¥14.56bn, demonstrating positive operating leverage. Net income attributable to owners increased 16.6% to ¥10.69bn. Gross profit margin improved 42bp year on year to 38.5%, from 38.1%. Operating margin expanded 111bp to 25.1%, from 24.0%. Net profit margin increased 96bp to 18.4%, from 17.5%. SG&A expense growth was limited to 5.1%, materially below revenue growth, supporting the margin expansion. The Electronic Materials and Functional Chemicals segment delivered 26.6% revenue growth and remained the principal profit engine. Its segment profit grew 21.2% to ¥12.45bn, accounting for approximately 76% of total segment profit before corporate-cost adjustments. Life Science revenue declined 4.0% to ¥26.40bn and segment profit declined 2.9% to ¥3.91bn, creating a clear divergence in business momentum. Cash earnings remain solid: operating cash flow was ¥15.18bn, equal to 1.42x net income, and free cash flow was ¥8.65bn. However, OCF/EBITDA cash conversion of 0.69x is below the 0.7x alert threshold, reflecting the cash absorbed by the operating asset base and working capital. Annualized receivable days of 87, inventory days reported at 137 days and a 203-day cash conversion cycle require close monitoring despite the favorable OCF-to-net-income ratio. The ¥2.94bn of PPE capex was only 0.40x depreciation, below replacement-level benchmarks; this is partly offset by ¥2.74bn of intangible-asset purchases, but sustained low tangible investment could become a capacity and asset-renewal issue. The balance sheet is exceptionally liquid, with a 373.7% current ratio, ¥36.73bn of cash and deposits, and debt/EBITDA of only 0.64x. Full-year guidance appears achievable, as Q3 cumulative revenue has reached 76.7% of the full-year target and operating income has reached 83.2%, versus a standard 75% seasonal progress rate. The key forward implication is that the company enters Q4 with substantial earnings headroom, but maintaining the high consolidated margin will depend on continued electronic-materials demand, working-capital discipline, and adequate reinvestment in production assets.

Profitability Analysis

Annualized ROE is 12.6%, decomposed into a 18.4% net profit margin, 0.517x annualized asset turnover, and 1.32x financial leverage. The return profile is therefore driven primarily by exceptionally high margins rather than leverage, which is a favorable quality characteristic. Financial leverage is conservative and indicates that the company is not relying on debt to generate shareholder returns. The largest favorable year-on-year movement is margin expansion: operating margin rose 111bp, exceeding the 42bp increase in gross margin because SG&A grew only 5.1% against 10.5% revenue growth. This demonstrates operating leverage and disciplined overhead absorption. The Electronic Materials and Functional Chemicals segment is the core business, producing ¥31.53bn of revenue and ¥12.45bn of segment profit. Its segment margin declined by approximately 170bp to 39.5% from 41.2%, although this was more than offset at the consolidated level by its high growth and corporate-cost leverage. Life Science generated ¥26.40bn of revenue and ¥3.91bn of segment profit; its segment margin improved about 20bp to 14.8%, despite a 4.0% decline in sales. The mix shift toward Electronic Materials and Functional Chemicals lifted group profitability even as that segment's own margin normalized modestly. EBITDA was ¥21.91bn and the EBITDA margin was 37.8%, underscoring substantial depreciation-heavy earnings capacity. The tax burden was 0.702, equivalent to a 29.8% effective tax rate, which is broadly normal. The interest burden of 1.046 reflects net non-operating income, including ¥3.11bn of interest income and ¥2.71bn of foreign-exchange gains, rather than debt pressure. Interest expense was only ¥0.95bn, and EBIT interest coverage was 153.11x. Ordinary income exceeded operating income by ¥5.11bn, or 3.5% of revenue, supported principally by interest and FX income; this is helpful but less recurring than operating profit. Profit before tax also included a net extraordinary gain of ¥1.62bn, primarily a ¥1.85bn gain on sale of securities, equivalent to approximately 1.5% of net income. No segment impairment or goodwill-related charge was reported. Under JGAAP, the disclosed EBITDA pre-goodwill amortization is unchanged at ¥21.91bn, consistent with no identified goodwill-amortization distortion.

Growth Assessment

Revenue growth was broad enough to produce a 10.5% increase in consolidated sales, but it was concentrated in Electronic Materials and Functional Chemicals. That segment added ¥6.62bn of sales year on year, while Life Science revenue fell by ¥1.11bn. Electronic Materials and Functional Chemicals therefore contributed more than the entire consolidated sales increase and is the key determinant of near-term growth sustainability. Its 26.6% growth rate suggests strong demand conditions, but the 170bp segment-margin decline indicates that mix, pricing, ramp-up costs, or product-cost pressure should be monitored as volumes scale. Life Science's 4.0% sales decline is the principal internal offset to the electronics-driven momentum, although its segment margin held slightly higher year on year. Gross profit rose 11.6%, ahead of sales, and operating income rose 15.6%, confirming that growth was profitable rather than solely volume-led. Full-year revenue guidance is ¥75.50bn, implying Q4 revenue of about ¥17.57bn; Q3 cumulative progress is 76.7%, only 1.7 percentage points above the normal 75% pace. Full-year operating-income guidance is ¥17.50bn, implying Q4 operating income of about ¥2.94bn; the 83.2% progress rate is 8.2 percentage points ahead of the normal pace, but not more than the 10-point deviation threshold. Ordinary-income progress is 85.6% and net-income progress is 87.6%, indicating that non-operating and extraordinary gains have also supported the year-to-date result. The profit outlook should therefore distinguish the durable operating improvement from the contribution of interest income, FX gains and the securities-sale gain. Production assets remain significant at 43.3% of total assets, consistent with a capital-intensive specialty-chemicals and electronic-materials operating model. Construction in progress was ¥3.96bn, representing approximately 6.1% of PPE, which indicates an active but not unusually large investment pipeline.

Financial Health

Financial health is strong. The current ratio of 373.7% and quick ratio of 306.6% indicate abundant near-term liquidity and provide a substantial buffer against working-capital volatility. Working capital was ¥55.35bn, supported by ¥36.73bn of cash and deposits, ¥18.32bn of receivables and ¥13.58bn of inventories. Total liabilities were only 24.3% of total assets, while total equity was ¥113.14bn and represented a 75.7% capital adequacy ratio. Debt-to-equity was a conservative 0.32x, well below the 2.0x warning level. Debt/capital was 11.0% and debt/EBITDA was 0.64x, both consistent with low balance-sheet risk. EBITDA interest coverage of 230.37x and EBIT interest coverage of 153.11x indicate negligible financing-cost stress. Current liabilities were ¥20.22bn against ¥75.58bn of current assets, so there is no apparent current-asset versus short-term-liability maturity mismatch. Long-term loans were ¥14.00bn, while current debt classification includes a ¥4.00bn current portion of long-term loans; cash balances provide ample refinancing and repayment capacity. Intangible assets increased ¥1.87bn, or 46.7% year on year, to ¥5.88bn. This increase is consistent with ¥2.74bn of intangible-asset purchases during the period and warrants monitoring for returns on digital, technology, or other intangible investment. Nevertheless, intangibles are only 3.9% of total assets, far below levels that would imply material balance-sheet concentration. No goodwill impairment or segment impairment was reported. Asset retirement obligations were ¥0.18bn, immaterial relative to ¥36.28bn of liabilities, limiting disclosed environmental-restoration liability exposure.

Notable B/S Changes

Intangible assets: +¥1.87bn (+46.7%) to ¥5.88bn — consistent with ¥2.74bn of intangible-asset purchases; monitor the earnings and cash-return contribution of these investments, although intangibles remain only 3.9% of total assets. Property, plant and equipment: -¥2.26bn (-3.4%) to ¥64.72bn — net PPE declined despite ¥2.94bn of capex because depreciation was ¥7.35bn; this supports the concern that current tangible investment is below depreciation. Construction in progress: -¥15.60bn (-79.7%) to ¥3.96bn — indicates commissioning or completion of a substantial prior investment program, which may partly explain the current low CapEx/depreciation ratio. Long-term loans: -¥2.90bn (-17.2%) to ¥14.00bn — leverage declined while earnings and equity increased, strengthening already conservative solvency. Cash and deposits: +¥5.43bn (+17.4%) to ¥36.73bn — positive free cash flow and conservative financing support a further increase in liquidity. Accounts receivable: +¥2.27bn (+14.1%) to ¥18.32bn — growth exceeds revenue growth and aligns with the elevated reported DSO; collection efficiency should be monitored. Finished goods: -¥0.48bn (-3.4%) to ¥13.58bn — the inventory balance declined modestly, but reported inventory-day alerts remain elevated because the stock level is still substantial relative to the production and sales cycle.

Cash Flow Quality

Cash-flow quality is favorable on the direct earnings-cash comparison: operating cash flow was ¥15.18bn, exceeding net income of ¥10.69bn by 42%, for an OCF/net-income ratio of 1.42x. The accruals ratio was -3.0%, which is consistent with cash realization exceeding accounting earnings. Free cash flow, defined using disclosed PPE capex, was ¥8.65bn and remained positive after investment spending. However, the low-cash-conversion alert must be addressed: OCF/EBITDA was 0.69x, slightly below the 0.7x threshold, showing that depreciation-backed EBITDA has not converted into cash at a fully robust rate. The gap is not an immediate earnings-quality failure because OCF exceeds net income, but it makes working-capital execution important. Receivables increased by ¥2.09bn in the operating cash-flow statement, and annualized DSO was reported at 87 days, above the 60-day warning level. This indicates slower cash collection or sales timing toward the end of the cumulative period and is a financial-risk consideration in a business with substantial electronics exposure. Inventory generated a ¥0.59bn operating-cash inflow, yet reported annualized inventory days were 137 days, above the 90-day warning threshold; a second provided inventory alert also identifies 104 days against a 60-day threshold. Both reported inventory-day signals point to elevated stockholding and potential demand, mix, or obsolescence risk, particularly for finished goods of ¥13.58bn. The reported annualized cash conversion cycle of 203 days is well above the 120-day alert level, combining high receivable and inventory duration and leaving cash conversion exposed to order timing and inventory turns. Trade payables decreased by ¥0.50bn, reducing supplier financing and contributing to the long cash cycle. The low CapEx/depreciation alert and duplicate capex-underinvestment alert are also material: PPE capex of ¥2.94bn equaled only 0.40x depreciation of ¥7.35bn, below the 0.7x warning level. This may reflect a temporary completion of a prior major investment phase, as prior-year PPE capex was substantially higher, but a persistent ratio at this level would raise maintenance, capacity and technology-renewal risk. Including ¥2.74bn of intangible purchases, total disclosed PPE and intangible investment was ¥5.69bn, improving the broader reinvestment picture but still remaining below depreciation. Cash dividends paid were ¥2.78bn, financing cash flow was negative ¥4.80bn, and cash increased by ¥4.41bn, reinforcing the company's strong internally funded liquidity position.

Dividend Sustainability

Dividend sustainability appears strong based on current earnings, free cash flow and balance-sheet liquidity. The Q2 dividend was ¥41 per share, and the disclosed cumulative dividend payout ratio was 13.6% of Q3 net income. This interim dividend was covered 5.94x by disclosed free cash flow. Full-year DPS guidance is ¥82, implying a forecast dividend payout ratio of approximately 23.7% based on forecast EPS of ¥346.04. That expected payout is conservative relative to earnings capacity and materially below the 60% sustainability benchmark. Using the full-year DPS guidance and the current share count, forecast aggregate dividends are approximately ¥2.91bn. This amount is comfortably covered by Q3 cumulative free cash flow of ¥8.65bn, even before considering the expected Q4 cash generation. Share repurchases were immaterial, so the distinction between dividend payout ratio and total return ratio has no practical effect in this period. Retained earnings of ¥99.30bn and cash and deposits of ¥36.73bn provide additional protection for dividends during cyclically weaker periods. The principal medium-term constraint is not funding capacity but whether low PPE capex persists and eventually requires a catch-up investment cycle. For now, the dividend framework leaves substantial capacity for capital investment, balance-sheet resilience and shareholder distributions.

Risk Assessment

Business risks include Electronic Materials and Functional Chemicals is the core earnings driver, contributing approximately 76% of segment profit before corporate costs; a semiconductor/electronics demand correction, customer inventory adjustment, pricing pressure or product-mix deterioration would have a disproportionate effect on consolidated earnings., Life Science revenue declined 4.0% year on year, indicating that growth is not presently balanced across the portfolio., Electronic Materials and Functional Chemicals segment margin declined approximately 170bp to 39.5% despite strong sales growth, creating risk that volume growth may not fully translate into incremental profitability if cost or mix pressure continues., Finished-goods inventory was ¥13.58bn, and elevated reported inventory days increase the risk of inventory aging, valuation losses or production adjustment if demand slows., As a chemical manufacturer, the company remains exposed to raw-material, energy, quality-control, environmental-regulation and product-specification risks; asset retirement obligations are currently immaterial but do not eliminate operational environmental risk., FX gains of ¥2.71bn contributed to non-operating income; exchange-rate movements can reverse this benefit and add volatility to ordinary income..

Financial risks include Reported annualized DSO of 87 days exceeds the 60-day warning threshold, indicating that receivables are tying up cash for an extended period., Reported annualized inventory days of 137 days, alongside a separate 104-day inventory alert, exceed applicable warning benchmarks and contribute to a reported 203-day cash conversion cycle., The 203-day annualized cash conversion cycle is above the 120-day warning threshold, increasing sensitivity of operating cash flow to collections, inventory turns and supplier-payment timing., OCF/EBITDA cash conversion of 0.69x is marginally below the 0.7x alert threshold, although OCF/net income of 1.42x and negative accruals mitigate immediate earnings-quality concerns., PPE CapEx/depreciation of 0.40x is below the 0.7x warning threshold. If sustained, this could defer required replacement investment and constrain future capacity or process modernization..

Key concerns include Highest priority: monitor electronics-market demand and the Electronic Materials and Functional Chemicals segment margin, because this segment is the dominant source of incremental revenue and profit., High priority: reduce the cash conversion cycle through receivable collection and finished-goods inventory management; this is the clearest operating-efficiency risk despite current strong liquidity., Medium priority: determine whether sub-replacement tangible capex reflects deliberate completion of a prior expansion cycle or persistent underinvestment., Medium priority: separate recurring operating performance from the ¥3.11bn interest income, ¥2.71bn FX gains and ¥1.85bn gain on sale of securities when evaluating earnings durability..

Investment Implications

Key takeaways include Revenue, operating income and net income grew 10.5%, 15.6% and 16.6%, respectively, with operating margin expanding to 25.1%., The core Electronic Materials and Functional Chemicals segment generated ¥12.45bn of segment profit on ¥31.53bn of sales, but its margin eased year on year., Operating cash flow exceeded net income and free cash flow was ¥8.65bn, supporting a conservative shareholder-distribution profile., Liquidity and credit metrics are exceptionally strong, including a 373.7% current ratio, 0.64x debt/EBITDA and 230.37x EBITDA interest coverage., Working-capital metrics and the 0.40x CapEx/depreciation ratio are the main financial-operating issues to monitor., Q3 operating-income progress of 83.2% against the full-year plan provides a favorable setup for meeting the ¥17.50bn full-year operating-income forecast..

Metrics to watch include Electronic Materials and Functional Chemicals revenue growth and segment margin, Life Science revenue stabilization and segment-profit trend, Annualized DSO, inventory days and cash conversion cycle, OCF/EBITDA cash conversion relative to the 0.7x threshold, PPE CapEx/depreciation and construction-in-progress conversion into productive assets, Contribution from FX gains, interest income and gains on sale of securities, Q4 operating income required versus the ¥17.50bn full-year forecast.

Regarding relative positioning, The company exhibits above-benchmark profitability for a manufacturer, with a 25.1% operating margin, 18.4% net margin and 12.6% annualized ROE achieved with low leverage. Its balance sheet and debt-service capacity are considerably more conservative than those of a typical capital-intensive manufacturer. Relative weaknesses are the extended reported working-capital cycle and low current tangible reinvestment rate, while earnings concentration in electronic materials increases sensitivity to that end market.